Clene/$CLNN
1D1W1MYTD1Y5YMAX
Capital at risk
About Clene
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
- Ticker
- $CLNN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Salt Lake City, United States
- Website
- clene.com
Clene Metrics
BasicAdvanced
$42M
-
-$3.50
0.97
-
Price and volume
Market cap
$42M
Beta
0.97
52-week high
$13.50
52-week low
$3.26
Average daily volume
100K
Financial strength
Current ratio
3.074
Quick ratio
2.237
Long term debt to equity
-0.852
Total debt to equity
-0.902
Interest coverage (TTM)
-7.13%
Profitability
EBITDA (TTM)
-19.118
Gross margin (TTM)
70.05%
Net profit margin (TTM)
-20,059.90%
Operating margin (TTM)
-10,431.98%
Management effectiveness
Return on assets (TTM)
-56.88%
Return on equity (TTM)
237.15%
Valuation
Price to revenue (TTM)
187.793
Price to book
-1.69
Price to tangible book (TTM)
-1.69
Price to free cash flow (TTM)
-2.32
Free cash flow yield (TTM)
-43.11%
Free cash flow per share (TTM)
-1.414
Growth
Revenue change (TTM)
-31.12%
Earnings per share change (TTM)
-1.73%
3-year revenue growth (CAGR)
-36.90%
3-year earnings per share growth (CAGR)
-35.72%
What the Analysts think about Clene
Analyst ratings (Buy, Hold, Sell) for Clene stock.
Analyst projections of the future price of Clene stock.
Clene Financial Performance
Revenues and expenses
Clene Earnings Performance
Company profitability
Upcoming events
No upcoming events
Clene News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.